PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1392014
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1392014
Skin Cancer Drugs Market, By Drug Type, By Cancer Type, By Route of Administration, By Distribution Channel, By Geography
Global skin cancer drugs market size is expected to reach US$ 15.32 Bn by 2030, from US$ 8.78 Bn in 2023, at a CAGR of 8.3% during the forecast period.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 8.78 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 8.30% | 2030 Value Projection: | US$ 15.32 Bn |
Skin cancer is a type of cancer that affects the skin cells and is primarily caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds. It is one of the most prevalent cancers globally, and its incidence has been increasing over the years. To combat this rising trend, pharmaceutical companies have been focusing on the development and innovation of skin cancer drugs.
Market Dynamics:
The skin cancer drugs market is primarily driven by the rising incidence of skin cancer worldwide. Factors such as excessive exposure to UV radiation, changing lifestyles, and an aging population contribute to the increasing prevalence of the disease. Moreover, advancements in therapeutic interventions and the introduction of targeted therapies have further fueled the market growth.
Market players are engaged in receiving approval from the regulatory authorities for the skin cancer drugs and this is expected to increase the growth of the global skin cancer drugs market, over the forecast period. For instance, in January 2021, Sun Pharma, a India based multinational pharmaceutical company, gained U.S. Food and Drug Administration (U.S. FDA) approval for Levulan Kerastick (aminolevulinic acid HCl) in combination with its "Light Emitting Diode" LED light source for photodynamic therapy (PDT) of minimally to moderately thick actinic keratosis of the face or scalp. It offers patients a less invasive treatment option.
However, there are several challenges that hinder the market growth. High drug development costs and stringent regulatory requirements pose significant barriers for new entrants. Adverse side effects associated with certain drugs and the availability of alternative treatment options act as restraining factors for market growth.
Despite these challenges, the market presents several opportunities for growth. Increasing investments in research and development (R&D) activities, along with collaborations between pharmaceutical companies and research institutions, are expected to drive innovation and the introduction of novel treatment options. Moreover, the growing focus on personalized medicine and the use of combination therapies offer potential avenues for market expansion.
Key features of the study:
- This report provides in-depth analysis of the global skin cancer drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global skin cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis, Merck, Roche, Amgen, Pfizer, Sun Pharma, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, Valeant, Daiichi Sankyo, Takeda Pharmaceutical, LEO Pharma, Mylan N.V., Sanofi, Regeneron, Eli Lilly, Bayer, Gilead Sciences and Astellas Pharma
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global skin cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin cancer drugs market
Detailed Segmentation:
- By Drug Type
- Chemotherapy Drugs
- Targeted Therapy Drugs
- Immunotherapy Drugs
- Hormone Therapy Drugs
- Others (Photodynamic Therapy, Cryotherapy and Others)
- By Cancer Type
- Basal cell carcinoma
- Squamous cell carcinoma
- Melanoma
- Others (Kaposi's sarcoma, Mycosis fungoides and Others)
- By Route of Administration
- Topical
- Oral
- Injectable
- Others (Surgical procedures, radiation therapy and Others)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Top Companies in Global Skin Cancer Drugs Market:
- Novartis
- Merck
- Roche
- Amgen
- Pfizer
- Sun Pharma
- Bristol-Myers Squibb
- AstraZeneca
- Johnson & Johnson
- Valeant
- Daiichi Sankyo
- Takeda Pharmaceutical
- LEO Pharma
- Mylan N.V.
- Sanofi
- Regeneron
- Eli Lilly
- Bayer
- Gilead Sciences
- Astellas Pharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Cancer Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing incidence of skin cancers
- High costs of targeted therapies
- Combination therapies
- Key Highlights
- Regulatory Scenario
- Recent Trends
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Skin Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Skin Cancer Drugs Market, By Drug Type, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Targeted Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Immunotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Hormone Therapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Others (Photodynamic Therapy, Cryotherapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
6. Global Skin Cancer Drugs Market, By Cancer Type, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Basal cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Squamous cell carcinoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Others (Kaposi's sarcoma, Mycosis fungoides and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
7. Global Skin Cancer Drugs Market, By Route of Administration, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Others (Surgical procedures, radiation therapy and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
8. Global Skin Cancer Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019 - 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Bn)
9. Global Skin Cancer Drugs Market, By Region, 2018-2030, (US$ Bn)
- Introduction
- Market Share Analysis, By Sub-region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Sub-region, 2019 -2030
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2018-2030,(US$ Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Company Profile
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck
- Roche
- Amgen
- Pfizer
- Sun Pharma
- Bristol-Myers Squibb
- AstraZeneca
- Johnson & Johnson
- Valeant
- Daiichi Sankyo
- Takeda Pharmaceutical
- LEO Pharma
- Mylan N.V.
- Sanofi
- Regeneron
- Eli Lilly
- Bayer
- Gilead Sciences
- Astellas Pharma
- Analyst Views
11. Section
- References
- Research Methodology
- About us
